Press Release
Article
Camber Pharmaceuticals Launches Generic Wellbutrin SR®
Camber Pharmaceuticals is pleased to announce the addition of Famotidine Powder for Oral Suspension, USP to its current portfolio.
Piscataway, NJ, November 27, 2023–Camber Pharmaceuticals is pleased to announce the addition of Famotidine Powder for Oral Suspension, USP to its current portfolio.
Famotidine Powder for Oral Suspension, USP is indicated:
In adults for the treatment of:
- active duodenal ulcer (DU).
- active gastric ulcer (GU).
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy.
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of DU recurrence.
In pediatric patients 1 year of age and older for the treatment of:
- peptic ulcer disease.
- GERD with or without esophagitis and ulcerations.
In pediatric patients from birth to less than 1 year of age for the treatment of:
- GERD.
Famotidine 40 mg/5 mL Powder for Oral Suspension, USP is available in a bottle to make 50 mL when reconstituted as directed.
To find out more about Famotidine Powder for Oral Suspension, USP please visit www.camberpharma.com/famotidine-pfos
